date:Sep 28, 2018
to the field, led by its recently approved medicine, Dupixent.
The drug targets two signaling molecules, interleukin 4 and interleukin 13, found to be overactive in allergic diseases like atopic dermatitis and asthma, explained Regeneron's president and chief scientific officer, Dr. George Yancopoulos.
It turns out the more specifically you can identify what's wrong with the immune system and what's overactive, you can target only that, Yancopoulos told CNBC in an interview. This is the defini